- Exicure to collaborate with Friedreich’s Ataxia Research Alliance (FARA) - Hank Paulson, MD, PhD and Susan Perlman, MD, added to Scientific Advisory Board Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced Friedreich’s ataxia (FA) as the therapeutic indication for… Read More..
Improved thermostabilized vaccine formulation advances into humans PRINCETON, N.J., Dec. 12, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened the study titled "A… Read More..
- Phase 1b/2 dose escalation trial of AST-008 shows tolerability of Exicure drug candidate - Preliminary data show signs of activity in patients with Merkel cell carcinoma - Exicure to proceed to Phase 2 study in Merkel cell carcinoma Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic… Read More..